Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The current study is to evaluate: Overall response rate for the combination of trastuzumab
and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and
tolerability of the combination; measure duration of tumor control and survival; assess
patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and
safety.